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Dysregulation of inlammatory responses is a hallmark of multiple diseases such as
atherosclerosis and rheumatoid arthritis. As constitutively active transcription factors,
NR4A nuclear receptors function to control the magnitude of inlammatory responses
and in chronic inlammatory disease can be protective or pathogenic. Within this study, 
we demonstrate that TLR4 stimulation using the endotoxin lipopolysaccharide (LPS)
rapidly enhances NR4A1–3 expression in human and murine, primary and immortalized 
myeloid cells with concomitant gene transcription and protein secretion of MIP-3α, a
central chemokine implicated in numerous pathologies. Deiciency of NR4A2 and
NR4A3 in human and murine myeloid cells reveals that both receptors function as
positive regulators of enhanced MIP-3α expression. In contrast, within the same cell
types and conditions, altered NR4A activity leads to suppression of LPS-induced MCP-1 
gene and protein expression. An equivalent pattern of inlammatory gene regulation is
replicated in TNFα-treated myeloid cells. We show that NF-κB is the critical regulator of 
NR4A1–3, MIP-3α, and MCP-1 during TLR4 stimulation in myeloid cells and highlight a 
parallel mechanism whereby NR4A activity can repress or enhance NF-κB target gene
expression simultaneously. Mechanistic insight reveals that NR4A2 does not require
DNA-binding capacity in order to enhance or repress NF-κB target gene expression
simultaneously and establishes a role for NF-κB family member Relb as a novel NR4A
target gene involved in the positive regulation of MIP-3α. Thus, our data reveal a dynamic 
role for NR4A receptors concurrently enhancing and repressing NF-κB activity in myeloid 
cells leading to altered transcription of key inlammatory mediators.
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inTrODUcTiOn
he NR4A family of nuclear receptors control inlammatory processes and function as impor-
tant transcriptional regulators in several disease states characterized by aberrant inlammation 
including atherosclerosis and arthritis (1–3). he NR4A family comprises three members, namely, 
NR4A1 (Nur77), NR4A2 (Nurr1), and NR4A3 (Nor-1). As orphan receptors, they have no known 
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endogenous ligand(s) and are regulated primarily at the level of 
gene transcription, posttranslational modiications, and pro-
tein–protein interactions (1–3). However, these receptors can be 
activated by select exogenous agents such as the photochemical-
based compound 1,1-bis (3′-indolyl)-1-(p-chlorophenyl) meth-
ane (C-DIM12), an NR4A2 activator, and the fungal metabolite 
Cytosporone-B (Csn-B), an NR4A1 agonist (4–6). hese recep-
tors control and limit inlammatory responses primarily by act-
ing as feedback regulators of NF-κB signaling, and more recently 
have been identiied as promoters of inlammatory resolution 
processes (1–3, 7). hus, pharmacological modulation of NR4A 
receptors has wide-ranging therapeutic potential to control 
hyperinlammatory responses associated with inlammatory 
diseases (1–3, 8).
NR4A receptors have profound efects on NF-κB, paradoxi-
cally repressing or enhancing its activity depending on tissue, 
cell type, or disease context (9–14). NR4A1 and 2 depletion pro-
motes polarization of macrophages toward a pro-inlammatory 
phenotype during TLR4 or TNFα stimulation, and this is associ-
ated with enhanced NF-κB activity (9–14). NF-κB enhancement 
is demonstrated through several mechanisms: increased nuclear 
translocation, phosphorylation, and DNA binding by NF-κB/
p65 leading to increased expression of key inlammatory genes 
including IL-12, iNOS, TNFα, IL-8, IL-6, and MCP-1 (9–14). 
Recently, it has been shown that NR4A3 depletion in myeloid 
cells parallels the responses observed by other family members 
during TLR4 stimulation, displaying enhanced expression 
of NF-κB-driven TNFα and MCP-1 (14). In contrast to these 
observations, Pei et  al. revealed that ectopic overexpression 
of NR4A1–3 in murine macrophage cells enhances lipopoly-
saccharide (LPS)-induced promoter expression of the pro-
inlammatory mediator IKKi (15). Furthermore, in rheumatoid 
arthritis synoviocyte cells, NR4A2 cooperates with NF-κB/p65 
to promote IL-8 production during TNFα receptor stimulation 
(10). Hence, the ability of NR4A1–3 receptors to repress or 
enhance NF-κB target gene expression highlights a dynamic 
relationship between these nuclear factors and the need for 
appropriate models when investigating the impact of NR4A 
activity on inlammatory outcome.
In this study, we focus on the role NR4A2 and NR4A3 recep-
tors play in regulating key inlammatory target gene expression 
and NF-κB activity in myeloid cells. TLR4 stimulation using the 
endotoxin LPS drives rapid expression of NR4A1–3 gene and pro-
tein expression in human and murine, primary and immortalized 
myeloid cells with concomitant expression of MIP-3α mRNA and 
protein release. Deiciency of NR4A2 and 3 reveals a novel role for 
NR4A receptors as important positive regulators of inlammatory 
driven MIP-3α in both human and murine myeloid cells. Within 
the same cell conditions, we reveal that NR4A2 and 3 function 
simultaneously as repressors of inlammatory-driven MCP-1. 
Furthermore, we demonstrate that NF-κB is the central tran-
scriptional regulator of NR4As, MIP-3α, and MCP-1 expression 
within TLR4-stimulated myeloid cells, conirming that depletion 
of NR4A receptor activity is capable of concurrent repression and 
enhancement of NF-κB target gene expression. NR4A2 does not 
require the ability to bind DNA in order to enhance or repress 
NF-κB target gene expression. Further investigations using 
mouse embryonic ibroblast (MEF) cells lacking p65, p50, p52, 
or Relb reveal that Relb is required to mediate MIP-3α expression. 
Furthermore, we establish NF-κB/p65 as a critical regulator of 
Relb during TLR4-driven responses. Our data highlight NR4A2 
and 3 as important receptors in the regulation of Relb in myeloid 
cells during TLR4 stimulation. his positive regulation of Relb by 
the NR4A receptors, coupled with the involvement of Relb in the 
regulation of MIP-3α, identiies a crucial mechanism in the dual 
activation/repression of NF-κB/NR4A target gene expression. 
Additionally, in vivo analysis demonstrates a signiicant increase 
in NR4A3 and MIP-3α expression speciically in internal carotid 
(IC) plaques from symptomatic patients. Subsequent PCR array 
analysis reveals that NR4A2 and 3 are key regulators of novel 
downstream target connective tissue growth factor (CTGF), an 
important atherogenic and ibrotic factor. Consistent with above 
mentioned target genes, we reveal that NF-κB, upstream of NR4A 
receptor activation, is the critical regulator of inlammatory-
driven CTGF. hus, we demonstrate the critical role NR4A genes 
play in modulating appropriate NF-κB target gene expression 
during inlammatory activation in myeloid cells.
MaTerials anD MeThODs
cell culture and Treatments
Human monocytic THP-1 and murine macrophage RAW 
264.7 cells obtained from American type culture collection 
(ATCC® TIB-202™ and TIB-71™, respectively) were cultured 
in RPMI-1640—GlutaMax™ media (Life Technologies™) and 
DMEM 6546 (Sigma-Aldrich®), respectively. MEF cells lacking 
NF-κB subunit p65 (p65−/−), p50 (p50−/−), p52 (p52−/−), Relb 
(Relb-/−), and wild-type (WT) controls were a generous git 
from Alexander Hofman (UCLA) and cultured in DMEM 6546 
(Sigma-Aldrich®). All cell media were supplemented with 10% 
FBS, 100  U/ml penicillin, and 100  µg/ml streptomycin. Cells 
were cultured at 21% O2, 5% CO2, and maintained in a humidi-
ied tissue culture incubator at 37°C balanced using nitrogen. 
Stable knockdown cells were maintained in an additional 5 µg/
ml Puromycin dihydrochloride (Sigma-Aldrich®) for stable 
knockdown selectivity. Reagents such as LPS, BAY-11-7082, and 
Cytosporone-b (Csn-B) were supplied by Sigma-Aldrich, and 
TNFα was supplied by RnD systems.
Primary cell isolation
Peripheral venous blood was collected from healthy volunteers 
at the Conway Institute, University College Dublin (UCD). 
Institutional review board approval was obtained from the Ethics 
Committee at St. Vincent’s University Hospital (UCD ailiated 
teaching hospital), and written informed consent was obtained 
from all volunteers. A total of 30 ml of blood was collected into a 
syringe, layered slowly onto polymorphoprep solution (1:1), and 
centrifuged at 500 × g for 35 min at 20°C with the brake of. he 
mononuclear layer was removed and mixed with equal volumes 
of 0.45% NaCl by gentle inversion followed by centrifugation at 
400 × g for 10 min at 20°C with the brake on. Supernatant was 
discarded and pellet was re-suspended in 12 ml ice-cold water 
and mixed by inverting gently for 1 min followed by the addition 
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of 12 ml 1.8% NaCl and subsequent centrifugation at 300 × g for 
5 min at 20°C with the brake on. Cells were then re-suspended in 
media, counted, and seeded at a density of 2.5 × 105 cells/ml for 
RNA experiments.
Patient recruitment and Deinition
he study was approved by the Ethics Committee of St. 
Vincent’s University Hospital, Dublin, and in accordance with 
International guidelines and Helsinki declaration principles. 
All patients (n = 6) gave written informed consent. his patient 
cohort has been recently described and analyzed (16). Patients, 
symptomatic and asymptomatic, with clinical and angiographic 
evidence of atherosclerosis undergoing revascularization surgery 
were recruited to the study, and clinical details obtained for 
patients are supplied as Table S1 in Supplementary Material. 
hree “symptomatic” patients [deined as patients who had had 
a irst-ever transient ischemic attack or non-disabling ischemic 
stroke from atherosclerotic stenosis and without any known 
history or diagnosis of cardiovascular disease (CVD)]; and three 
“asymptomatic” patients (deined as those without any previous 
ischemic events or known CVD) were studied.
Tissue specimen Preparation
Immediately following carotid endarterectomy, human carotid 
atherosclerotic plaque specimens were placed in RNAlater® solu-
tion (hermo Fisher), and stored at −80°C. Each plaque specimen 
was then dissected into four distinct sections: common carotid 
(CC), Internal Carotid (IC), external carotid (EC), and relatively 
disease free (RDF), as shown in the schematic (Figure S3A in 
Supplementary Material). Subsequent analysis was performed 
on IC and RDF samples only as described below in qRT-PCR 
methods.
stable lentiviral Knockdown
Stable knockdown of human NR4A2, NR4A3, and murine 
NR4A2 was achieved with the transduction of shRNA using a 
Mission™ Lentiviral packaging mix as per instructions (Sigma-
Aldrich) using THP-1. For controls, cells were transduced with 
scrambled shRNA (Sigma-Aldrich). Briely, for THP-1 cells, 
150 µl of cells from a stock concentration of 2.5 × 105 cells/ml 
were pipetted into a 96-well plate; for Raw mac 264.7 cells, 250 µl 
of cells from a stock concentration of 1.5 ×  105  cells/ml were 
pipetted into a 24-well plate and both were incubated overnight. 
Hexadimethrine bromide was added to a inal concentration of 
8 µg/ml followed by the addition of 10 µl of lentiviral particles 
and subsequent incubation for 48 h in a tissue culture incubator 
at 37°C. Subsequent to this, puromycin was added to the cells 
(5 µg/ml), and medium was changed every 3–4 days until resist-
ant colonies were identiied and subsequently expanded. Western 
blotting was used to conirm knockdown levels for human THP-1 
cells and qRT-PCR was used for murine Raw mac 264.7.
Transient Transfections
Mouse embryonic ibroblast cells were transfected with previ-
ously described/published plasmids p-CMX-NR4A2 (WT) 
and p-CMX-NR4A2 mutant (C283G) (10, 17). MEF cells were 
trypsinized, spun down to obtain pelleted cells, re-suspended 
in fresh media, and brought to a inal cell concentration of 
1.2 ×  10  cells/ml. Optimem, plasmid, and transfection reagent 
(TransIT2020) (Mirus) were mixed and let for 30  min to 
allow complexes to form as per manufacturer’s instructions in 
the ratio 100  μl:500  ng:3  μl (Optimem:Plasmid:TransIT2020). 
Subsequently 100 µl of mixture/complexes was added to 2 ml of 
cell suspension in 6-well plates and incubated for 48 h. At 48 h, 
cells were treated as described in igure legends.
Western Blotting
Whole-cell lysates: suspension cells (THP-1) were pelleted by 
centrifugation @ 1,200  RPM followed by re-suspension into 
100 µl radio-immuno-precipitation assay (RIPA) bufer. he re-
suspended pellets were then pipetted back onto their respective 
treatment dishes and were scraped into a new Eppendorf tube to 
ensure collection of loating cells and cells that adhered during 
the course of stimulations. Adherent cells (Raw mac 264.7) and 
MEFs were scraped directly into RIPA bufer. Cell suspensions 
were then agitated vigorously on a rocker for 30 min at 4°C fol-
lowed by centrifugation at 15,000 × g for 15 min. Supernatants 
were removed as whole-cell extracts and stored at −20°C.
Protein content was assessed by the Bradford method (Bio-
Rad Laboratories) and electrophoresed on 10% SDS PAGE gel 
followed by transfer to nitrocellulose membranes (Bio-Rad). 
Protein expression levels were measured by Western blot analysis 
using speciic antibodies for NR4A2 and NR4A3 (RnD systems); 
p65 (Cell Signaling); Relb (Cell Signaling); CTGF (Santa Cruz); 
and β-tubulin (Sigma). Briely, nitrocellulose membranes were 
incubated with primary antibodies overnight at 4°C followed 
by washing three times for 10 min with 1× TBST [20 mM Tris, 
137 mM NaCl, and 0.05% (v/v) tween 20] and subsequent incu-
bation for 1 h with species-speciic HRP-conjugated secondary 
antibodies at room temperature. Membranes were washed 
again as described followed by signal detection using enhanced 
chemiluminescence reagent (Pierce). Densitometric analysis 
included for Western blot data was determined using LI-COR® 
Image Studio Lite version 3.1. Briely, the intensity of proteins 
of interest (NR4A2, NR4A3, p65, Relb, and CTGF) was quanti-
ied using LI-COR program relative to loading control protein 
(β-tubulin).
elisa
Medium from THP-1-treated cells was centrifuged briely to 
remove cell debris, and supernatant was stored at −20°C. MCP-1 
and MIP-3α (RayBiotech) protein levels were measured using an 
enzyme-linked immunosorbent assay. IFNγ, IL-12p70, IL-10, 
IL-1β, IL-6, IL-8, and TNFα were measured using the Human 
ProInlammatory 7-Plex Tissue Culture Kit (MSC). ELISA was 
performed as per manufacturer’s instructions. Changes incorpo-
rated into the protocols speciic for our data are as follows. For 
each ELISA, the dilution value was calculated to yield optimum 
results within the linear range of the assay. From this, we deter-
mined that samples were used neat on the 7-Plex ELISA, diluted 
1:10 for MCP-1 and 1:6 for MIP-3α.
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qreal-Time Pcr (qrT-Pcr)
RNA was extracted from in vitro cells using the column-based 
EZNA® total RNA extraction kit (Omega Bio-Tek, GA, USA). 
Trizol (Invitrogen) extraction was used to isolate total RNA from 
patient samples stored in RNAlater®. cDNA synthesis was sub-
sequently performed as previously reported (14). qRT-PCR was 
performed using SYBR Green Master Mix (Applied Biosystems) 
and on an ABI 7300 thermocycler (Applied Biosystems). Primer 
pair sequences used are detailed in Table S2 in Supplementary 
Material. Relative expression/abundance levels of target gene 
transcripts were determined using qBase plus sotware (Biogazelle, 
Ghent University, Belgium) with GAPDH or β-actin (in  vitro 
samples) or ribosomal 18s (patient samples) as a reference target. 
Results are expressed as fold over untreated control (FOC).
Pcr array
An in-house PCR array, consisting of 92 inlammatory genes 
and 4 reference genes, was performed. For this array, cDNA 
synthesis was performed using 500 ng of total RNA using the RT2 
First Strand Kit (Qiagen Ltd.) according to the manufacturer’s 
instructions. Real-time reverse transcriptase PCR was performed 
on a 20 µl reaction mixture per well containing 1 µl cDNA (ater 
1:5 dilution), 9 µl water, and 10 ml RT2 SYBR Green/ROX qPCR 
master mix (SABiosciences) in a 7300 Real-time PCR system 
(Applied Biosystems). Using a web-based PCR array data analy-
sis tool (SABiosciences), the CT values of the target genes were 
normalized against the four reference genes (GAPDH, HPRT1, 
TBP, and ACTB) and the relative abundance of gene transcripts 
were calculated as log2CT. Subsequently, expression fold changes 
were calculated as fold over untreated control sample (FOC) and 
are displayed in Table S3 in Supplementary Material, alongside 
raw CT values. Using the PCR array data tool, a clustergram was 
made and displayed in Figure 6A. A clustergram performs non-
supervised hierarchical clustering of the entire data set and is 
represented as a heat map with a dendrogram showing individual 
genes and overall treatment groups with a similar regulation 
pattern.
Promoter studies and analysis
he Genomatix sotware suite program MatInspector 
(© Genomatix Sotware GmbH) was used to analyze the human 
and murine MIP-3α promoter 500 bp upstream of the transcrip-
tion start site (TSS). Two stringency tests were applied as per 
Genomatix sotware instructions in order to select binding sites 
that displayed the best probability as “real” binding motifs for 
transcription factors (Core similarity of 1.0 and matrix similarity 
>0.90). he irst test is the core similarity test and the maximum 
core similarity of 1.0 is only reached when the highest conserved 
bases of a matrix match exactly in the given sequence. he second 
test is the matrix similarity test and the score must be greater 
than 0.90.
statistical analysis
All data is presented as mean ± SEM and representative Western 
blots for a minimum of three individual n numbers (unless 
otherwise stated). Statistical signiicance was performed using a 
two-tailed Student’s t-test for patient tissue analysis and one-way 
analysis of variance followed by Tukey’s post hoc test was utilized 
throughout all other results (GraphPad Prism®).
resUlTs
Tlr4 stimulation Drives nr4a gene and 
Protein expression in Myeloid cells
TLR4 ligands, including LPS, have been shown to drive NR4A 
gene expression in immune cells (14, 18). Several studies have 
shown in both human and mouse macrophages, using NR4A1–3 
overexpression and/or knockout cells, that NR4A receptors 
regulate expression of several downstream NF-κB target genes 
including IKKi, TNFα, MCP-1, iNos, IP-10, and IL-12 (9, 11, 
13–15). NR4A family members can modulate NF-κB activity 
downstream of TLR4 signaling in a dynamic fashion, either 
repressing or enhancing NF-κB target gene expression (9, 11, 
13–15). he majority of the work to date suggests that NR4A1 
and 2 depletion promotes a pro-inlammatory macrophage 
phenotype, displaying enhanced NF-κB activity (9, 11, 13–15). 
However, there are minimal studies elucidating the role mono-
cyte/macrophage NR4A3 plays in modulating such regulatory 
pathways.
To examine TLR4-driven NR4A2 and NR4A3 gene and 
protein expression, we utilized a range of human myeloid cells 
including primary human mononuclear cells (PBMCs), THP-1s, 
Phororbol-12-myristate-13-acetate (PMA) diferentiated THP-1s, 
and murine RAW mac264.7 cells. In human PBMCs, we reveal 
temporal changes in NR4A1–3 gene expression in response to 
LPS (1.0 µg/ml) (Figure 1A). We observe NR4A1 gene expres-
sion rises sharply and signiicantly at 1  h and is reduced by 2 
and 3 h. NR4A2 gene expression is signiicantly increased at 1 h 
albeit to a very low level, while NR4A3 gene expression is sig-
niicantly increased at 1, 2, and 3 h post stimulation (Figure 1A). 
Examining PMA (20  nM) diferentiated THP-1 cells reveals a 
signiicant induction of all NR4A family members at 2 h exposed 
to 1.0  µg/ml LPS (Figure  1B). Using undiferentiated THP-1 
cells, we observe a signiicant and selective induction of NR4A2 
and 3 gene expression within 2  h LPS (100  ng/ml) treatment 
(Figure 1C) with minimal changes in NR4A1 expression.
hus, we examined temporal levels of NR4A2 and 3 protein 
expression in undiferentiated THP-1 cells exposed to LPS 
(1.0  μg/ml) (Figure  1D). Undiferentiated THP-1 cells were 
chosen for extended analysis based on their similarity to the 
expression proile observed in primary PBMCs for NR4A recep-
tors in response to LPS. Additionally, we have previously shown 
undiferentiated THP-1 cells closely relect primary cell responses 
to various stimuli such as LPS and adenosine and support that 
they are a relevant immortalized cell line to use in such myeloid 
cell studies (14). NR4A3 protein is dramatically increased within 
4 h and maintained at 6 h post LPS, while NR4A2 is enhanced as 
early as 2 h with protein levels reducing over 4–6 h (Figure 1D) 
revealing distinct temporal changes in protein expression under 
these cellular conditions. We and others have shown previously 
that LPS-driven NR4A transcription is NF-κB dependent (14, 18). 
FigUre 1 | Tlr4 stimulation drives nr4a genes in monocyte/macrophage cells. (a) Human primary PBMCs were exposed to 1 µg/ml lipopolysaccharide 
(LPS) for 1, 2, and 3 h. (B) THP-1 cells differentiated using 20 ng/ml PMA were exposed to 1 µg/ml LPS for 2 h. (c) Undifferentiated THP-1 cells were exposed to 
100 ng/ml LPS for 2 h. (D) Undifferentiated THP-1 cells transduced with shRNA directed against scrambled non-target control, NR4A2, or NR4A3 were treated with 
1 µg/ml LPS for 0, 2, 4, and 6 h. Additionally, scrambled non-target control cells were pretreated with NF-κB inhibitor BAY-11-7082 (NF-κBi) (10 µM) for 1 h followed 
by 4 h 1 µg/ml LPS. Whole-cell lysates were then prepared from all treatments. (e) Murine raw mac 264.7 cells were pretreated with (NF-κBi) (10 µM) for 1 h 
followed by exposure to 1 µg/ml LPS for 1 h. Analysis: RNA was isolated at indicated time and RT-PCR was performed to assess levels of NR4A1, 2, 3, and control 
gene GAPDH (a–c,e). Western blot analysis was performed on whole-cell lysates for NR4A2, NR4A3, and loading control β-Tubulin (D). Densitometric analysis 
included for Western blot data was determined using LI-COR® Image Studio Lite version 3.1, and band density of target proteins (NR4A2 and NR4A3) normalized to 
loading control (β-Tubulin) are displayed above relevant treatments (n = 2). Data are expressed as fold over untreated control (FOC) ± SEM for n = minimum of three 
individual experiments or representative Western blot for n = minimum of two individual experiments. *p < 0.05, **p < 0.01, ***p < 0.001 treatments compared to 
untreated control (Un).
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Here, we support the studies conirming that pretreatment with 
the NF-κB inhibitor BAY 11-7082 (10 µM) abolishes LPS-driven 
NR4A2 and 3 protein expression (Figure 1D). We next examined 
the expression of NR4A genes in response to LPS in the murine 
macrophage cell line Raw Mac 264.7 (Figure  1E). LPS (1  µg/
ml) signiicantly drives NR4A1 and NR4A2 gene expression 
within 1 h; in contrast, NR4A3 mRNA levels remain unchanged 
(Figure 1E). Using the NF-κB inhibitor BAY 11-7082 (NF-κBi) 
(10  µM), we further establish that LPS-induced NR4A1/2 is 
NF-κB dependent in these cells (Figure 1E).
NR4A2 and 3 virally delivered shRNA depleted cells were 
utilized (14) to further identify the transcriptional role of NR4A2 
and 3 in TLR4 driven gene expression. As shown in Figure 1D, 
which incorporates NR4A2/3 depleted cells alongside scrambled 
control cells, we demonstrate a signiicant depletion of NR4A2 
(≈96%) and NR4A3 (≈79%) (% calculated from densitometry 
band intensity values) (Figure 1D). Taken together, we establish 
that LPS drives temporal expression of NR4A1–3 genes in human 
and murine myeloid cells and further demonstrate that LPS-
driven NR4A2 and 3 expression is NF-κB dependent.
nr4a receptors negatively and Positively 
regulate nF-κB Target gene expression 
simultaneously
NR4A receptors have the ability to promote or repress NF-κB 
target gene expression, albeit to date such divergent mechanisms 
have been established distinctly, and not simultaneously. We 
therefore investigated the efect of NR4A depletion on a number 
of known NF-κB target genes in myeloid cells. A multiple ELISA 
was performed to quantify IFNγ, IL-12p70, IL-10, IL-1β, IL-6, 
IL-8, TNFα, and additional single ELISA for MCP-1 and MIP-3α 
expression levels. hese targets were selected having identiied 
them as NF-κB-regulated genes using the NF-κB inhibitor BAY-
11-7082 in THP-1 cells [data not shown, Figure 2 and Ref. (9, 
14)]. Second, NR4A receptors have been shown to be critical 
FigUre 2 | nr4a2 and 3 negatively regulate Tlr4 driven McP-1 in human and murine myeloid cells. (a,B) Undifferentiated THP-1 cells transduced with 
shRNA directed against scrambled non-target control, NR4A2, or NR4A3 were treated with 1 µg/ml lipopolysaccharide (LPS) for 18 h (B) and 24 h (a), followed by 
media collection and RNA isolation, respectively. (c) Undifferentiated THP-1 cells were pretreated with 10 µM NF-κB inhibitor (NF-κBi) for 1 h followed by the 
addition of 1 µg/ml LPS for 24 h, followed by media collection. (D) Murine raw mac 264.7 cells transduced with shRNA directed against scrambled non-target 
control and NR4A2 were exposed to LPS for 1 h. (e) Murine raw mac 264.7 cells transduced with shRNA directed against scrambled non-target control and NR4A2 
were exposed to 1 µg/ml LPS for 2 h. (F) Murine raw mac 264.7 cells were pretreated with 10 µM NF-κB inhibitor (NF-κBi) for 1 h followed by exposure to 1 µg/ml 
LPS for 2 h. Analysis: ELISA analysis was performed for MCP-1 protein detection on media collected at times indicated (a,c). RNA was isolated and RT-PCR was 
performed at indicated times to assess levels of MCP-1 NR4A2 and control gene GAPDH (B,D–F). Un, untreated control. Data are expressed as fold over untreated 
control (FOC) or pg/ml ± SEM for n = minimum of three individual experiments. *p < 0.05, **p < 0.01, ***p < 0.001 treatments compared to untreated control (Un). 
###p < 0.01, ###p < 0.001 treatments compared displayed here using a bar attachment.
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in regulating their appropriate expression during inlammatory 
responses by our group and others (3, 9, 10, 14, 19).
ELISA analysis reveals NR4A2 and 3 depletion results in a more 
pronounced TLR4 response, displaying enhanced LPS-driven 
IL-12p70, Il-1β, IL-10, TNF-α, and IL-6 protein secretion (Figure 
S1 in Supplementary Material). We also observed enhanced pro-
tein secretion and mRNA expression of MCP-1 within NR4A2 
and 3 depleted cells, which was more profound than any of the 
other targets described above (Figures 2A,B). Furthermore, we 
show that this LPS-induced MCP-1 is inhibited by the use of 
the NF-κB inhibitor BAY-11-7082 (NF-κBi), conirming MCP-1 
to be an NF-κB-dependent gene (Figure  2C). As NR4A2 and 
NR4A3 display distinct expression changes in murine Raw mac 
264.7 cells (Figure  1E), stably depleted NR4A2 cell line was 
selected using viral delivery of shRNA directed against NR4A2 
and scrambled control. Gene expression analysis reveals that 
95% depletion of LPS (1  µg/ml) induced NR4A2 gene expres-
sion in NR4A2 shRNA-transduced cells compared to scrambled 
control (Figure 2D). We further reveal scrambled Raw mac 264.7 
cells exposed to LPS for 1  h results in signiicant MCP-1 gene 
expression, and this regulation is further potentiated with NR4A2 
depletion (Figure 2E). Additionally, using the NF-κB inhibitor 
BAY 11-7082 (NF-κBi), we show that LPS-driven MCP-1 in Raw 
mac 264.7 cells is also NF-κB dependent (Figure 2F).
Intriguingly however, having demonstrated that NR4As 
negatively regulate the above NF-κB target genes, we observe 
LPS-dependent secretion of MIP-3α protein is signiicantly 
attenuated in NR4A2 and NR4A3 depleted cells (p ≤ 0.05 and 
p ≤ 0.01, respectively) (Figure 3A). Further analysis shows LPS 
drives MIP-3α gene expression within 2 h and expression returns 
to basal levels by 8  h. However, this induction is signiicantly 
attenuated (≈50%) in cells depleted of NR4A2 or NR4A3 expres-
sion (Figure 3B). Additionally, we observe a signiicant induction 
in MIP-3α gene expression in human PBMCs treated with 1 µg/
ml LPS for 2 h (Figure 3C). Furthermore, LPS signiicantly drives 
MIP-3α mRNA in undiferentiated THP-1 cells and use of the 
FigUre 3 | nr4as positively regulate Tlr4 driven MiP-3α in human and murine monocyte/macrophage cells. (a) Undifferentiated THP-1 cells 
transduced with shRNA directed against scrambled non-target control (Sc), NR4A2 (A2), or NR4A3 (A3) were treated with 1 µg/ml lipopolysaccharide (LPS) for 8 h, 
followed by media collection. (B) Undifferentiated THP-1 cells transduced with shRNA directed against scrambled non-target control, NR4A2, or NR4A3 were 
treated with 1 µg/ml LPS for 0, 2, and 8 h. (c) Human primary PBMCs were exposed to 1 µg/ml LPS for 2 h. (D) Undifferentiated THP-1 cells were pretreated with 
10 µM NF-κB inhibitor (NF-κBi) for 1 h followed by the addition of 1 µg/ml LPS for 2 h. (e,F) Mouse embryonic ibroblast (MEF) cells lacking p65−/− and wild-type 
(WT) controls were exposed to 1 µg/ml LPS for 4 h (e) and 2 h (F). (g) Murine raw mac 264.7 cells transduced with shRNA directed against scrambled non-target 
control (pretreated with 10 µM NF-κB inhibitor (NF-κBi) for 1 h) and NR4A2 were subsequently treated with of 1 µg/ml LPS for 1 h. (h) MEF cells lacking p65−/− and 
WT controls were exposed to 1 µg/ml LPS for 2 h. (i,J) Undifferentiated THP-1 cells were pretreated with 100 nM Cytosporone-B (Csn-b) for 30 min followed by the 
addition of 100 ng/ml LPS for a further 1.5 h. Analysis: ELISA was performed at time indicated for MIP-3α protein (a). RNA was isolated and RT-PCR was 
performed at indicated times to assess levels of MIP-3α, NR4A2, NR4A3, TNFα, and control gene GAPDH (B–D,F,h,i,J). Whole-cell lysates were prepared at 
indicated time followed by Western blot analysis performed for both p65 and loading control β-tubulin (e). Densitometric analysis included for Western blot data was 
determined using LI-COR® Image Studio Lite version 3.1 and band density of target protein (p65) normalized to loading control (β-Tubulin) are displayed above 
relevant treatments. Un, untreated control. Data are expressed as fold over untreated control (FOC) or pg/ml ± SEM for n = minimum of three individual 
experiments. **p < 0.01, ***p < 0.001 treatments compared to untreated control (Un). #p < 0.05, ##p < 0.01, ###p < 0.001 treatments compared displayed here 
using a bar attachment.
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NF-κB inhibitor, BAY 11-7082 (NF-κBi) (10 µM), conirms this 
induction is NF-κB dependent (Figure 3D). To further support 
NF-κB-dependent regulation of MIP-3α, we utilized mouse 
embryonic ibroblast (MEF) cells lacking the NF-κB subunit 
p65 (p65−/−) and WT control (Figure 3E). We demonstrate that 
LPS drives MIP-3α gene expression in WT MEF cells and that 
this induction is abolished in the p65−/− MEF cells (Figure 3F). 
Raw mac 264.7 cells exposed to 1 µg/ml LPS for 1 h results in 
a signiicant induction of MIP-3α gene expression and that this 
induction is signiicantly attenuated in NR4A2-depleted cells 
(Figure 3G). Using the NF-κB inhibitor BAY 11-7082 (NF-κBi) 
(10 µM), LPS-driven MIP-3α is shown to be NF-κB dependent 
in Raw mac 264.7 cells (Figure 3G). Importantly, using the MEF 
cells lacking the NF-κB subunit p65 (p65−/−) analysis conirms 
a signiicant reduction in LPS-driven MIP-3α gene expression 
compared to WT control (Figure  3F), and here we reveal that 
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NR4A2 and NR4A3 expression is also reduced in the MEF p65−/− 
cells during TLR4 stimulation using LPS compared to WT cells 
(Figure 3H).
In order to address the role of NR4A1 in mediating MIP-3α 
expression, we utilized the NR4A1 agonist Cytosporone-B (Csn-
B). We conirm Csn-B activity within our cell system by examin-
ing the expression of TNFα, previously shown to be repressed 
by NR4A1 activity in myeloid cells (20). Here, we conirm that 
Csn-B co-treatment signiicantly attenuates LPS-driven TNFα 
(Figure 3I). Further analysis reveals that stimulation of THP-1 
cells with LPS (100 ng/ml), in the presence of Csn-B, does not 
signiicantly alter MIP-3α induction (Figure 3J).
We next investigated whether this diferential regulation of 
NF-κB targets by NR4A receptors was speciic to LPS-TLR4-
driven inlammatory responses by using TNFα in the above 
systems. Here, we reveal that TNFα drives MIP-3α expression 
and protein secretion in primary and THP-1 cells (Figures S2A,B 
in Supplementary Material). Additionally, we show that TNFα-
driven MIP-3α is NF-κB dependent using the BAY 11-7082 
NF-κB inhibitor (Figure S2C in Supplementary Material). We 
observe analogous regulation of MIP-3α expression in both 
scrambled control and NR4A2/3 depleted cells, demonstrating 
that this regulatory mechanism is not limited to TLR4 signal-
ing (Figure S2D in Supplementary Material). Furthermore, we 
observe a similar pattern of regulation of MCP-1 in scrambled 
and NR4A2/3 depleted cells in response to TNFα (Figures S2E,F 
in Supplementary Material).
We have established using myeloid cells the involvement of 
NR4A2/3 receptors in the regulation of MIP-3α downstream 
of TLR4 or TNFα signaling. To expand these observations, 
we sought to examine the expression proile of NR4A2/3 and 
MIP-3α expression in  vivo in human carotid plaque tissue, 
given the fact that both genes have been identiied as important 
factors in the pathogenesis of atherosclerosis (21–25). Figure 
S3A in Supplementary Material identiies the speciic regions 
of the carotid where portions examined are taken from, IC 
or RDF from asymptomatic and symptomatic patients, as 
described within the Section “Materials and Methods.” Our 
analysis reveals that, in symptomatic plaques, NR4A3 and 
MIP-3α expression is signiicantly elevated in the IC-diseased 
portion compared to their respective RDF or IC sections from 
asymptomatic patients. Interestingly, NR4A2 expression is not 
signiicantly increased in symptomatic patients compared to 
asymptomatic tissue (Figure S3B in Supplementary Material). 
herefore, NR4A2 and NR4A3 in  vitro have been shown to 
regulate MIP-3α gene expression, while in vivo, speciic NR4A3 
expression levels parallel MIP-3α expression suggesting NR4A3 
may be involved in an in  vivo setting, albeit patient numbers 
are limited and the role of NR4A3 regulating MIP-3α in such 
disease warrants further investigation.
hus, data herein strengthen the hypothesis that NR4As 
are not merely repressors or enhancers of NF-κB target genes 
in isolation but can lead to distinct cellular outcomes by both 
positive and negative modulation of target gene expression con-
currently. hus, NR4A2 and 3 are key regulators of MIP-3α gene 
expression in human and murine myeloid cells. We demonstrate 
that NR4A2 and 3 receptors concurrently enhance and repress 
NF-κB-dependent target gene expression, positively regulating 
MIP-3α while negatively regulating targets such as MCP-1.
nr4a2 Does not require Dna-Binding 
capacity to Differentially regulate nF-κB 
Target gene expression
In order to investigate how NR4As were positively regulating 
MIP-3α expression in both human and murine, we performed 
promoter analysis using the Genomatix MatInspector sotware 
suite. Figure 4A shows a graphical representation obtained from 
Genomatix showing two NBRE (NR4A-binding motif) and one 
κB (NF-κB-binding motif) site on the human MIP-3α proximal 
promoter, and on NBRE and κB site on the murine promoter. 
Intriguingly, no NBRE sites were identiied in the promoters of 
the negatively regulated NR4A target genes IL-12P70 (analyzed 
IL-12p40 and p35 subunits), IL-10, TNF-α, IL-6, and MCP-1, 
while one NBRE site was identiied in IL-1β (data not shown). 
Expanded from this graphic is the sequence of both human and 
murine showing the NBRE and κB sites identiied nearest the TSS 
of both promoters (Figure 4A). We and others have previously 
shown that p65 is capable of binding to this κB site nearest the 
TSS (14, 26).
Following this, we investigated whether NR4A receptors 
needed to bind their NBRE motif in order to enhance MIP-3α 
expression. Using MEF cells, we overexpressed p-CMX-NR4A2 
WT plasmid and a mutant p-CMX-NR4A2 (C283G) plasmid, 
previously published by our group and others, which lacks the 
ability to bind to the NBRE sequence on DNA (10, 17). MEF cells 
displayed successful transfection with signiicant increases in 
NR4A2 mRNA in both WT and mutant over backbone control 
(278 ±  105- and 202 ±  49-fold over control, respectively). We 
reveal that overexpression of WT NR4A2 can enhance MIP-3α 
gene expression during LPS stimulation and the DNA-binding 
mutant NR4A2 does not efect this enhancement (Figure  4B). 
Furthermore, we show that IL-6 expression due to LPS stimula-
tion is suppressed in both WT and mutant NR4A2 (Figure 4B). 
Importantly, we conirm using the MEF cells lacking p65−/− that 
LPS-driven IL-6 in these cells is NF-κB dependent (Figure 4C). 
hus, NR4A2 does not require the ability to bind to DNA in order 
to enhance or repress NF-κB target gene expression.
nr4a2 and 3 are Positive regulators of 
nF-κB Family Member relb during Tlr4 
stimulation
Following the knowledge that NR4A2 does not require DNA 
binding to enhance and repress NF-κB target gene expression, 
we decided to examine more extensively the regulatory elements 
involved in MIP-3α production. In order to do this, we used MEF 
cells lacking the NF-κB family members p65−/−, p50−/−, p52−/−, 
and Relb−/−. We have shown that MIP-3α is NF-κB subunit p65 
dependent in MEF cells (Figure 3F); additionally, we show that 
LPS-driven MIP-3α is also NF-κB subunit p50 dependent (data 
not shown), clearly identifying that it is a canonical NF-κB target 
gene. Furthermore, we identify that LPS is still capable of driving 
MIP-3α expression in MEF cells lacking p52−/− (data not shown), 
FigUre 4 | nr4a2 does not require Dna binding in order to regulate Tlr4-driven MiP-3α. (a) Graphical representation [showing ≈500 bp upstream and 
≈200 downstream of the transcription start site (TSS) (TSS is indicated on graphic as a black arrowhead)] of the NR4A (shown as yellow box) and NF-κB (shown as 
purple box) DNA-binding motifs (NBRE and NRE, respectively) on the MIP-3α human and murine promoter analyzed using the Genomatix software suite program 
MatInspector for 1,000 bp upstream of the TSS. Expanded out regions marked by a blue lined box is ≈200 bp upstream of TSS showing the exact sequence of the 
NR4A and NF-κB-binding motifs. Human and murine promoter are shown aligned using the ApE plasmid editor software, red boxes indicate gaps, and red boxes 
with a # indicate a mismatch. (B) Mouse embryonic ibroblast (MEF) cells were transfected with 500 ng of wild-type (WT) p-CMX-NR4A2, p-CMX-NR4A2 mutant 
(C283G), and backbone control plasmid (BB). Following 48 h incubation, cells were treated with 1 µg/ml lipopolysaccharide (LPS) for 2 h. (c) MEF cells lacking 
p65−/− and WT controls were exposed to 1 µg/ml LPS for 2 h. Analysis: RNA was isolated and subsequent qRT-PCR performed to assess levels of MIP-3, IL-6, and 
control gene β-actin (B,c). Data are expressed as fold over untreated control (FOC) ± SEM for n = minimum of 2 (B) and 6 (c) individual experiments. *p < 0.05, 
**p < 0.01 treatments compared to untreated control (Un). #p < 0.05 treatments compared displayed here using a bar attachment.
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however intriguingly we show cells lacking Relb−/− display 
signiicantly attenuated MIP-3α expression (Figure 5A). Given 
that MIP-3α in these cells is conirmed as a p65-dependent gene, 
we examined whether Relb was also regulated in this manner. 
Here, we reveal that LPS stimulation signiicantly drives Relb 
protein and gene expression in a NF-κB p65-dependent manner 
(Figures 5B,C). Additionally, we observe that LPS-driven Relb is 
NF-κB p50-dependent (data not shown). Figure 5B also includes 
the Relb−/− MEF cells to conirm that the cells lack Relb expres-
sion. Furthermore, we show that LPS can drive Relb expression 
in THP-1 cells and that this is NF-κB dependent, shown using the 
NF-κB inhibitor BAY 11-7082 (Figure 5D). We also show that 
Relb gene expression is induced following LPS stimulation using 
primary PBMC cells (Figure 5E), conirming that this induction 
is an observation not limited only to immortalized THP-1 and 
MEF cells.
FigUre 5 | nr4as are regulators of relb expression during Tlr4 stimulation. (a) Mouse embryonic ibroblast (MEF) cells lacking p65−/− and wild-type (WT) 
control were exposed to 1 µg/ml lipopolysaccharide (LPS) for 2 h. (B) MEF cells lacking p65−/−, Relb−/−, and WT control were exposed to 1 µg/ml LPS for 4 h. 
(c) MEF cells lacking Relb−/− and WT control were exposed to 1 µg/ml LPS for 2 h. (D) Undifferentiated THP-1 cells were pretreated with 10 µM NF-κB inhibitor 
(NF-κBi) for 1 h followed by the addition of 1 µg/ml LPS for 2 h. (e) Human primary PBMCs were exposed to 1 µg/ml LPS for 2 h. (F) Undifferentiated THP-1 cells 
transduced with shRNA directed against scrambled non-target control, NR4A2, or NR4A3 were treated with 1 µg/ml LPS for 2 h. Analysis: RNA was isolated and 
RT-PCR was performed at indicated times to assess levels of MIP-3α, Relb, and control gene GAPDH (a,c–F). Whole-cell lysates were prepared at indicated time 
followed by Western blot analysis performed for both Relb and loading control β-tubulin (B). Densitometric analysis included for Western blot data was determined 
using LI-COR® Image Studio Lite version 3.1, and band density of target protein (Relb) normalized to loading control (β-Tubulin) are displayed above relevant 
treatments. Un, untreated control. Data are expressed as fold over untreated control (FOC) ± SEM for n = minimum of three individual experiments. **p < 0.01, 
***p < 0.001 treatments compared to untreated control (Un). #p < 0.05, ###p < 0.001 treatments compared displayed here using a bar attachment.
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Taking into account that NR4As are positive regulators of 
MIP-3α in THP-1 (NR4A2 and 3), Raw mac 264.7, and MEF cells 
(NR4A2 only tested), we asked whether they were involved in 
LPS-driven Relb expression. Here, we reveal for the irst time that 
Relb is a novel NR4A target gene, displaying a signiicant reduc-
tion in expression during LPS stimulation in the both NR4A2 and 
3 depleted cells (Figure 5F). hus, we have identiied that MIP-3α 
is both a NR4A and Relb target gene during LPS stimulation, and 
further reveal that NR4As are important in the LPS regulation of 
Relb itself. Importantly, we show that NF-κB subunits p65 and 
p50 (canonical NF-κB) are upstream of all of these factors.
nr4a2 and 3 are Positive regulators of 
Fibrotic and atherogenic Factor cTgF
In order to expand our knowledge of NR4A2/3 regulated target 
genes during inlammatory pathogenesis, we performed an 
in-house PCR array. Scrambled control THP-1 cells, NR4A2 
and 3 depleted cells were stimulated with LPS (100 ng/ml) for 
2  h. A heat map represents changes in gene expression from 
the array and similarities in the pattern of gene regulation and 
overall treatment similarities are represented by the inclusion 
of a dendrogram (Figure 6A). All data obtained from the PCR 
array analysis are shown in Table S3 in Supplementary Material. 
Genes of interest were further investigated within the same 
experimental model and analyzed using qRT-PCR (Figure 6B). 
LPS signiicantly drives CTGF in scrambled control THP-1 cells, 
and this induction is signiicantly attenuated in NR4A2 and 3 
depleted cells (Figure 6B). Intriguingly while LPS treatment alone 
does not alter PAI-1 expression, an established NR4A1 regulated 
target gene in human umbilical vein endothelial cells, MCF-7, 
and JURKAT cells during TNFα stimulation (27), NR4A2 deple-
tion signiicantly potentiates LPS efects on PAI-1gene expression 
and NR4A3 depleted cells display signiicantly reduced PAI-1 
levels. Using the NR4A1 agonist Csn-B (100 nM), we reveal that 
enhanced NR4A1 activity reduces CTGF expression (Figure 6C).
Here, we establish that TLR4 stimulation drives CTGF 
expression, an important atherogenic and ibrotic factor, and 
for the irst time show NR4A receptor activity is crucial to this 
induction. To further characterize the mechanisms involved 
FigUre 6 | nr4as are key regulators of inlammatory driven cTgF. (a) Undifferentiated THP-1 cells transduced with shRNA directed against scrambled 
non-target control (Sc), NR4A2 (A2 dep), or NR4A3 (A3 dep) were treated with 100 ng/ml lipopolysaccharide (LPS) for 2 h. RNA was isolated was from 3 technical 
replicates, pooled, and a PCR array (consisting of 92 targets and 4 reference genes) was performed. Using a web-based PCR array data analysis tool 
[SABiosciences, Qiagen], a clustergram was made. A clustergram performs non-supervised hierarchical clustering of the entire data set and is represented as a heat 
map with a dendrogram showing individual genes and overall treatment groups with a similar regulation pattern. (B) Genes of interest were then investigated using 
qRT-PCR on three separate experiments (n = 3) following the same protocol used in the array described above. (c) Undifferentiated THP-1 cells were pretreated 
with 100 nM Cytosporone-B (Csn-B) for 30 min followed by the addition of 100 ng/ml LPS for a further 1.5 h. (D) Undifferentiated THP-1 cells were exposed to 
1 µg/ml LPS for 0, 2, 4, and 6 h. (e) Undifferentiated THP-1 cells transduced with shRNA directed against scrambled non-target control, NR4A2, or NR4A3 were 
treated with 1 µg/ml LPS for 4 h. (F,g) Undifferentiated THP-1 cells were pretreated with 10 µM NF-κB inhibitor (NF-κBi) for 1 h followed by the addition of 1 µg/ml 
LPS for 2 h (F) or 4 h (g). Analysis: (B,c,F) RNA was isolated at times indicated and RT-PCR was performed at indicated times to assess levels of CTGF, PAI-1, and 
control gene GAPDH. Whole-cell lysates were then prepared from all treatments and Western blot analysis was performed for CTGF and loading control β-Tubulin 
(D,e,g). Data are expressed as fold over untreated control (FOC) ± SEM for n = minimum of three individual experiments or representative Western blot for 
n = minimum of three individual experiments. *p < 0.05, **p < 0.01, ***p < 0.001 treatments compared to untreated control (Un). ###p < 0.001 treatments compared 
displayed here using a bar attachment. Blue arrow demonstrates where CTGF is on the heat map, and orange arrow indicates where PAI-1 is. Un, untreated control; 
Dep, depleted.
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in this regulation, we establish that LPS (1 µg/ml) signiicantly 
drives CTGF protein expression as early as 2 h and this induc-
tion declines over 4 and 6  h (Figure  6D). Further analysis 
supports the changes in gene expression using the PCR array, 
whereby LPS (1 µg/ml) induces CTGF protein expression at 4 h, 
which is signiicantly attenuated in NR4A2 and 3 depleted cells 
(Figure 6E). Using the NF-κB inhibitor BAY 11-7082 (10 µM), 
we conirm that LPS (1 µg/ml) and TNFα-induced CTGF gene 
FigUre 7 | summary diagram. TLR4 or TNFα receptor stimulation increases the activity of NF-κB and the expression of its target genes NR4A1–3 (NR4A), 
MCP-1, MIP-3α, and Relb. Loss of NR4A potentiates this induction of MCP-1, while reducing the induction of Relb and MIP-3α. Furthermore using mouse 
embryonic cells, we identify MIP-3α is a novel Relb target gene. Therefore, NR4A receptors act as repressors of inlammatory-NF-κB-driven MCP-1 (indicated by a 
red T bar) and enhancers of NF-κB-driven Relb and subsequently MIP-3α. Using a NR4A2 DNA-binding mutant reveals that NR4A2 does not require the ability to 
bind DNA in order to enhance/repress target genes simultaneously.
12
McEvoy et al. NR4A Receptors Differentially Regulate NF-κB
Frontiers in Immunology | www.frontiersin.org January 2017 | Volume 8 | Article 7
and protein expression is NF-κB dependent (Figures  6F,G; 
Figure S4 in Supplementary Material), consistent with other 
LPS-induced targets controlled by NR4A activity including 
MIP-3α and MCP-1. We next examined whether CTGF was a 
Relb target gene, similar to that of MIP-3α, the other positively 
regulated NR4A gene identiied in this study. Unfortunately 
however, examination of the MEF cells reveals no enhancement 
of CTGF during LPS stimulation, a mechanism that may be cell 
type speciic and therefore we could not investigate the Relb 
involvement using these MEF Relb−/− cells. Moreover, promoter 
analysis shows no NR4A DNA-binding motifs (NBRE sites) 
on the promoter of CTGF (data not shown). hus, we have 
identiied NR4A receptors regulate novel target gene CTGF, an 
important ibrotic and atherogenic target gene.
DiscUssiOn
Dysregulation of an appropriate inlammatory response plays a 
critical role in the pathogenesis of diseases such as atheroscle-
rosis and rheumatoid arthritis. Using NR4A depleted human 
and murine myeloid cells, alongside MEF cells overexpressing 
NR4A2, we reveal that these receptors are capable of dynamic 
regulation of NF-κB target genes including MIP-3α and MCP-1, 
as summarized in Figure 7. NR4A receptors negatively regulate 
MCP-1 and positively regulate key inlammatory chemokine 
MIP-3α simultaneously during TLR4 or TNFR stimulation. 
Employing an inlammatory PCR array, we reveal a new target 
gene CTGF, a key ibrotic and atherogenic factor, to be positively 
regulated by the NR4A receptors. Intriguingly, both NR4A3 and 
MIP-3α have been shown to play crucial roles in the pathogenesis 
of atherosclerosis, and here, we show an enhancement and cor-
relation in gene expression of both in carotid plaques from symp-
tomatic patients. Mechanistic investigations reveal that NR4A2 
does not require DNA binding in order to simultaneously 
enhance or repress NF-κB target gene expression. Furthermore, 
we reveal the NF-κB family member Relb to be a novel NR4A 
target gene during TLR4 stimulation and that Relb is critical in 
the regulation of MIP-3α. hus, we reveal a complex dynamic, 
whereby NR4A receptors can simultaneously enhance or repress 
NF-κB target gene expression, and that they do not need to bind 
DNA in order to do so and Relb, acting as a novel NR4A target, 
may be important in this dynamic system.
Within the nuclear hormone receptor family, the NR4A 
receptor subfamily, which includes NR4A1, NR4A2, and NR4A3, 
has emerged as key regulators of inlammatory responses (1–3). 
NR4A family members attenuate LPS and TNFα stimulated 
pro-inlammatory response in myeloid cells principally limiting 
NF-κB activation (3). We and others have shown that NR4A 
expression is increased by LPS stimulation in myeloid cells 
(14, 18). Here, we support these observations showing that 
LPS stimulation drives all three NR4A genes in primary and 
immortalized human and murine monocyte/macrophage cells. 
Within this study, we further reveal that LPS-driven NR4A genes 
in human and murine myeloid cells is NF-κB dependent. We 
have recently reported that depletion of NR4A2 and 3 in human 
monocyte cells results in a hyper-pro-inlammatory cell pheno-
type, displaying enhanced NF-κB target genes TNFα and MCP-1 
protein secretion during LPS stimulation (14). his study sup-
ports and expands these observations showing that NR4A2 and 
3 depletion in myeloid cells results in enhanced NF-κB-driven 
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IL-12p70, Il-1β, IL-10, TNF-α, IL-6, and MCP-1 gene expression. 
he repressive mechanism of NR4As has been examined reveal-
ing NR4As recruit co-repressor complex CoREST to NF-κB on 
its target genes, subsequently limiting its transcriptional activity 
(11). Collectively, we describe how NR4A genes are regulated 
by NF-κB in order to feedback/limit downstream target gene 
expression. his study therefore expands and supports growing 
observations in several cell types deciphering this feedback 
regulatory loop, which is needed to control the magnitude of 
inlammatory responses (11, 12, 14, 19).
Intriguingly, NR4A receptors can enhance NF-κB activity 
and subsequent target gene expression, with NR4A2 enhanc-
ing IL-8 through cooperation with p65 in rheumatoid arthritic 
synoviocyte cells (10). Maijenburg et al. also revealed through 
gain of function experiments that NR4A1 and 2 can increase 
both IL-8 and IL-6 production in mesenchymal stromal cells, 
albeit the role of NF-κB was not determined (28). Within this 
study, we demonstrate that LPS and TNFα stimulation drives 
gene and protein secretion of chemokines MIP-3α and MCP-1 
in primary and immortalized human and murine (LPS only) 
myeloid cells. We further identify NF-κB to be the upstream 
regulator of both chemokines within these conditions and cells 
consistent with previous studies in myeloid and other cell types 
(14, 26, 29, 30). Interestingly, we observed using depleted cells 
that NR4A2 and 3 were positive regulators of inlammatory-
driven MIP-3α in human THP-1 cells and murine RAW264.7 
macrophage cells (NR4A2 only), while repressors of MCP-1 as 
stated above. Additionally, overexpression of NR4A2 in MEF 
cells supports its role as a regulator of LPS driven MIP-3α 
expression.
We have recently shown that adenosine drives NR4A receptor 
expression in myeloid cells, primarily through the A2a receptor 
(14). Furthermore, THP-1 cells exposed to LPS or TNFα and 
subsequently treated with adenosine receptor A2a agonist dis-
play increased NF-κB-dependent MIP-3α expression. Analysis 
revealed that depletion of NR4A2 within this model results in 
further enhancement of MIP-3α expression with concurrent 
NF-κB/p65 binding to its promoter (14). Additionally, using 
vascular SMCs, it has recently been shown that overexpression 
of NR4A3 can attenuate LPS-driven MIP-3α production (19). 
Importantly, herein we reveal that NR4A2 and 3 can act as 
positive regulators of MIP-3α expression in human and murine 
myeloid cells during TLR4 or TNFα receptor stimulation, and 
furthermore, this regulation is governed by NF-κB activity. 
Promoter analysis reveals NR4A and NF-κB-binding motifs 
(NBRE and NRE, respectively) on the MIP-3α promoter in 
both human and murine species. Taking this into account, we 
investigated whether NR4A receptors are needed to bind to the 
MIP-3α promoter, at their consensus motif in order to posi-
tively regulate its expression. Using a mutant NR4A2 plasmid 
(C293G), which lacks the ability to bind DNA (10, 17), along-
side a WT control, we revealed that NR4A2 did not require the 
ability to bind DNA in order to enhance LPS driven MIP-3α, 
while simultaneously repressing NF-κB target gene IL-6. he 
ability of NR4A receptors to enhance gene expression while not 
binding DNA has been shown previously and we support these 
observations (10).
In order to gain more mechanistic insight, we utilized MEF 
cells lacking all NF-κB family members p65, p50, p52, and Relb. 
We reveal that LPS-induced MIP-3α is not only p65 regulated 
but also p50 (displaying canonical pathway regulation) and more 
interestingly Relb dependent. Moreover, we show that Relb is 
induced by LPS in MEF and myeloid cells and that this regulation 
is dependent upon canonical NF-κB family members. Herein, 
we support previous studies showing inlammatory mediators 
such as LPS or TNFα can induce Relb in myeloid cells, and some 
studies revealing the canonical NF-κB family are involved in this 
regulation (31–34). We reveal that NR4A depletion in THP-1 
cells results in attenuated MIP-3α with enhanced IL-6 protein 
secretion, and overexpression of NR4A2 in MEF cells shows the 
inverse during LPS stimulation. Intriguingly, Tully et al. revealed 
in lung epithelial cells that Relb depletion resulted in enhanced 
IL-6 production alongside attenuated MIP-3α production (32). 
Here, we show this phenomenon is paralleled in NR4A-depleted 
cells, and furthermore, we reveal Relb to be a novel NR4A 
target gene during LPS stimulation. hus, this study highlights 
a more complex model of NR4A–NF-κB interaction in myeloid 
cells. Highlighting the ability for NR4A2 and 3 to enhance and 
repress NF-κB target genes simultaneously, independent of DNA 
binding, in same cell types exposed to distinct pro-inlammatory 
stimuli. Finally, we show Relb to be a novel NR4A target gene 
during LPS responses, and given that it can also enhance/repress 
inlammatory genes simultaneously, we speculate this may be a 
component of how NR4As are performing such an action.
In order to expand our analysis, with the aim of identifying 
more NR4A positively/negatively regulated genes during LPS 
stimulation, we utilized a PCR array consisting of 92 inlam-
matory genes. From this evaluation, we observed NR4A2 and 3 
to be positive regulators of key ibrotic and atherogenic factor, 
CTGF (35–38) during LPS stimulation. Using bronchial epithelial 
cells, LPS has previously been shown to regulate CTGF through 
NF-κB (39). Within this study, we reveal for the irst time, to our 
knowledge, LPS stimulated CTGF in myeloid cells is NR4A2 and 
3 dependent and is regulated as early as 2 h and declines by 6 h, 
prototypical of an immediate early gene response. Further analysis 
reveals that this regulation is co-ordinated by NF-κB, which sup-
ports previous studies using bronchial epithelial cells (39). Recent 
evidence has emerged highlighting the pivotal role NR4A1 plays 
in ibrosis, speciically impacting on the TGFβ1 pathway (40), 
given CTGF is an important factor inluencing both ibrosis and 
the TGFβ1 pathway (35, 36), we speculate NR4A2 and 3 may also 
play roles in ibrotic disease and is currently under investigation 
in our laboratory.
hus, NR4A receptors are key regulators of inlammatory 
signaling, primarily modulating NF-κB activity. Here, we reveal 
NR4As are capable of simultaneously directing NF-κB target gene 
expression, enhancing MIP-3α and CTGF while repressing MCP-1 
and other major inlammatory chemokines and cytokines. We 
reveal novel data showing NR4As can regulate LPS-driven Relb 
and that Relb is involved in LPS-driven MIP-3α. Additionally, 
we show that NR4As do not require the ability to bind DNA in 
order to simultaneously enhance and repress NF-κB target gene 
expression. Such an observation identiies a greater complexity 
to how NR4A receptors can efect NF-κB signaling. his study 
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